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2211-3355/© 2016 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oAvailable online 30 December 2015 Objective: To assess whether bodymass index (BMI) modiﬁes the associations of lipids with coronary heart dis-
ease (CHD).
Methods: In the Asia Paciﬁc Cohort Studies Collaboration, total cholesterol (TC), high density lipoprotein choles-
terol (HDLC) and triglycerides (TG)were measured for 333,297, 71,777 and 84,015 participants, respectively. All
participants had measured BMI, categorized into underweight, normal, high-normal, overweight and obese,
using standard deﬁnitions. For each BMI subgroup the effects of lipids on CHDwere estimated per 1 standard de-
viation (SD) increase using Cox proportional hazard models, stratiﬁed by study and sex, adjusted for age and
smoking. They were compared across the BMI groups, testing for interactions.
Results: In the analyses for TC, HDLC and TG, therewere 3121, 714 and 808 CHD events during amean follow-up
of 6.7 years. The risk of CHD increased monotonically with increasing TC and decreasing HDLC in all BMI sub-
groups without evidence of heterogeneity (p for interaction N0.4). In contrast, the hazard ratio for CHD for a
one SD increase in log-transformed TG increased from 1.07 (95%CI 0.72–1.59) in underweight, 1.26 (1.10–
1.44) in normal weight, 1.27 (1.08–1.49) in high-normal weight, 1.37 (1.22–1.55) in overweight, to 1.61(1.30–
1.99) in obesity (p = 0.01 for interaction trend). These associations were attenuated (p = 0.07 for interaction)
but remained signiﬁcant in the overweight and obese after further adjustment for TC and HDLC.
Conclusions: Greater excess body weight exacerbated the effects of TG, but not TC or HDLC, on CHD, suggesting
that additional effort is required to reduce TG in the overweight and obese.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Pooled analysisIntroduction
Overweight and obesity are consistently shown to be associated
with high morbidity and mortality for coronary heart disease (CHD)
(Ni Mhurchu et al., 2004), with 23% of the global burden of CHDGlobal Health, PO Box M201,
tralia. Tel.: +61 2 9993 4514;
oodward).
. This is an open access article underattributable to overweight/obesity (World Health Organization, 2009).
Dyslipidemia is also an established risk factor for CHD (Zhang et al.,
2003; Woodward et al., 2007; Patel et al., 2004), with more than half
of global cases attributed to it (World Health Organization, 2002). Over-
weight/obesity is likely to co-occurwith dyslipidemia,(Bays et al., 2013)
through their common linkage with unfavorable lifestyles and through
accumulated visceral fat that promotes insulin resistance and subse-
quent hyperinsulinemia, the key factor for lipid disorders in obesity
(Klop et al., 2013). Additionally, one might hypothesize that obesity
could intensify the association of dyslipidemia with subsequent risk of
CHD but current evidence on such effect modiﬁcation is lacking.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Baseline characteristics of Asian and Australasian (Australia and New Zealand) regions.
Risk factors Asia Australasia Overall
Analysis set for total cholesterol
No. of participants 249,206 84,091 333,297
Age, year 45.9 (9.1) 50.5 (13.0) 47.0 (10.4)
Female, % 37.7 51.6 41.2
Smoker, % 37.8 18.4 32.9
Body mass index, kg/m2 22.9 (2.8) 26.3 (4.3) 23.7 (3.6)
Total cholesterol, mmol/l 4.9 (1.0) 5.6 (1.1) 5.1 (1.0)
Systolic blood pressure, mmHg 123.2 (17.0) 134.1 (20.6) 126.0 (18.6)
Diabetes mellitus, % 6.9 4.0 6.2
Follow-up period, years 5.6 (3.6) 10.0 (6.1) 6.7 (4.8)
Analysis set for HDL cholesterol
No. of participants 48016 23761 71777
Age, year 50.3 (12.1) 47.6 (14.7) 49.4 (13.1)
Female, % 44.2 50.3 46.2
Smoker, % 33.7 23.6 30.3
Body mass index, kg/m2 22.9 (3.4) 25.7 (4.3) 23.8 (3.9)
HDL cholesterol, mmol/l 1.4 (0.4) 1.4 (0.4) 1.4 (0.4)
Systolic blood pressure, mmHg 126.2 (21.0) 129.8 (20.2) 127.4 (20.8)
Diabetes mellitus, % 6.3 2.9 5.2
Follow-up period, year 6.2 (3.5) 9.4 (4.9) 7.2 (4.3)
Analysis set for triglycerides
No. of participants 65832 18183 84015
Age, year 49.6 (12.2) 46.2 (15.6) 48.9 (13.1)
Female, % 47.3 50.4 48.0
Smoker, % 32.6 23.7 30.7
Body mass index, kg/m2 22.9 (3.3) 25.4 (4.2) 23.4 (3.7)
Triglycerides, mmol/l 1.2 (0.8–1.7) 1.2 (0.8–1.7) 1.2 (0.8–1.7)
Systolic blood pressure, mmHg 126.0 (21.0) 128.9 (20.2) 126.6 (20.9)
Diabetes mellitus, % 5.6 2.9 5.0
Follow-up period, year 7.9 (4.6) 9.8 (5.5) 8.3 (4.9)
HDL cholesterol, high density lipoprotein cholesterol.
Values are mean (standard deciation) for continuous variables except median (interquar-
tile interval) for triglycerides, and percentage for categorical variables.
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using data from the Asia Paciﬁc Cohort Studies Collaboration (APCSC).
Methods
APCSC is an overview, using individual participant data, of prospec-
tive cohort studies from the Asia-Paciﬁc region. APCSC's design and
methods have been previously described in detail (Ni Mhurchu et al.,
2004; Zhang et al., 2003; Woodward et al., 2007; Patel et al., 2004). All
studies had 5000+ person-years of follow-up. Studies were excluded
if enrolment was dependent on having a particular condition or a risk
factor. The present report included participants aged ≥20 years with in-
formation on BMI, smoking status and either total cholesterol (TC),
high-density lipoprotein cholesterol (HDLC) or triglycerides (TG) at
study entry, measured in 34, 25 and 26 studies, respectively, among
the 44 studies included in the APCSC.
BMI was calculated as weight (kg) divided by squared height (m2).
Participants at extremes of the BMI spectrum (b12 or N60 kg/m2)
were excluded (Parr et al., 2010). Smoking statuswas deﬁned as current
or not. Lipid measurements were determined from serum samples,
among which b10% were non-fasting. Since the studies were initiated
between 1966 and 1994, the assays for TC, HDLC and TG varied
(Zhang et al., 2003; Woodward et al., 2007; Patel et al., 2004). SBP was
generally measured at rest in the seated position using a standard mer-
cury sphygmomanometer. Diabetes was taken as present either from a
self-reported history, elevated fasting glucose greater than 6.1 mmol/l
for serum samples, and greater than 7mmol/l for plasma samples, or el-
evated non-fasting glucose greater than 10 mmol/l for serum samples,
and greater than 11.1 mmol/l for plasma samples.
All studies reported deaths by underlying cause; a subset also re-
ported nonfatal CHD events. Most studies used database linkages to
identify deaths, whereas others also included scheduled follow-up visits
or examined hospital records, particularly to identify nonfatal events,
deﬁned as those that did not result in death within 28 days. The out-
come considered in this analysis was fatal or nonfatal CHD (Ninth Revi-
sion of International Classiﬁcation of Disease: 410–414).
Statistical methods
Cox proportional hazard models, stratiﬁed by sex and cohort, were
used to estimate the joint effects of lipid variables and BMI on
CHD risk. Age and smoking status were adjusted for in all analyses.
BMIwas categorized into 5 groups based on theWorldHealth Organiza-
tion criteria for Asia-Paciﬁc populations: (WHO/IASO/IOTF, 2000)
12.0 ≤ BMI b 18.5, underweight; 18.5 ≤ BMI b 23.0, normal;
23.0 ≤ BMI b 25.0, high-normal; 25.0 ≤ BMI b 30.0, overweight; and
30.0 ≤ BMI b 60.0 kg/m2, obese.Within each category of BMI, hazard ra-
tios (HRs) with 95% conﬁdence intervals (CIs) for CHD were estimated
by quarters of each lipid: TC b 4.4; 4.4 ≤ TC b 5.0, 5.0 ≤ TC b 5.8,
TC ≥ 5.8 mmol/l; HDLC b 1.1, 1.1 ≤ HDLC b 1.4, 1.4 ≤ HDLC b 1.6,
HDLC ≥ 1.6 mmol/l; TG b 0.9, 0.9 ≤ TG b 1.2, 1.2 ≤ TG b 1.7,
TG ≥ 1.7mmol/l. The joint effects of lipid variableswith BMIwere exam-
ined by comparing the HRs for CHD across the 20 groups (4 × 5 catego-
ries) taking the group with the lowest 25% of values for the index lipid
variable and with normal weight (i.e. either TC b 4.4 mmol/l,
HDLC b 1.1 mmol/l or TG b 0.9 mmol/l and 18.5 ≤ BMI b 23.0 kg/m2)
as the reference group. HRs were also estimated per standard deviation
increment for each lipid variable within each category of BMI and were
compared across these categories by testing the trend for interaction of
the continuous lipid variable with BMI categories (Woodward, 2015).
Sensitivity analyses were done after left-censoring by 2 years to reduce
the chance of reverse causality; after excluding participants with non-
fasting blood samples; and after adjusting for systolic blood pressure
(SBP) and diabetic status, aswell as age and smoking status. Further ad-
justment was also made for the other two lipids in addition to other
confounders. Heterogeneity of the linear interactions between lipidsand BMI were tested between subgroups deﬁned by age groups
(≤65 years/N65 years, sex (male/female), smoking status (current/
not) and region (Asia/Australia and New Zealand) by adding three-
way interaction terms to Coxmodels with all two-way interactions. Sta-
tistical analyses were performed using SAS Release 9.30 (SAS Institute
Inc, Cary, NC).
Results
Overall, 333,297 individuals contributed to the analyses of TC,
71,777 to those of HDLC, and 84,015 to those of TG (Table 1). Mean
follow-up was 6.7, 7.2, and 8.3 years for TC, HDLC and TG, respectively.
Mean age was 47–49 years, about half of participants were female, and
70% were Asian. Mean BMI at baseline varied, between studies, from
21.5 to 26.9 kg/m2, mean TC from 4.1 to 5.9 mmol/l, mean HDLC from
0.9 to 1.6 mmol/l andmedian TG from 0.7 to 1.5 mmol/l (Supplementa-
ry table 1). On average, BMI and TC were higher in those cohorts
sourced from Australia or New Zealand compared with those from
Asia,whereas average levels of HDLC and TGwere similar betweenAus-
tralasia and Asia.
The effects of BMI on the association between total cholesterol and coronary
heart disease
The age and smoking-adjusted HR for CHDwas higher in the highest
quarter of TC compared with the lowest quarter among all BMI catego-
ries (Supplementary Figure 1). There was no difference in the effects of
TC between BMI categories (p = 0.42 for trend); overall, for every 1
standard deviation increase in TC therewas a 23% (95% CI, 20%–27%) in-
crease in the risk of CHD (Fig. 1). Similar associations were obtained in
the sensitivity analyses after left-censoring by 2 years (Supplementary
Figure 2), after excluding participants with non-fasting blood samples
(Supplementary Figure 3) and after further adjustment for SBP and
BMI (kg/m2) P for trend HR (95% CI)
Number of 
events / subjects
1.00.5 2.0
Total cholesterol
12.0 – 18.4 77  / 11352
18.5 – 22.9 778  / 140535
23.0 – 24.9 626  / 79288
25.0 – 29.9 1248  / 84638
30.0 – 60.0 392  / 17488
Overall 0.42 3121  / 333297
HDL cholesterol
12.0 – 18.4 26  / 3794
18.5 – 22.9 183  / 28546
23.0 – 24.9 149  / 15051
25.0 – 29.9 261  / 19539
30.0 – 60.0 95  / 4847
Overall 0.95 714  / 71777
Triglycerides
12.0 – 18.4 40  / 4812
18.5 – 22.9 248  / 36318
23.0 – 24.9 170  / 17950
25.0 – 29.9 265  / 20761
30.0 – 60.0 85  / 4174
Overall 0.01 808  / 84015
1.25 (1.06, 1.47)
1.25 (1.18, 1.32)
1.27 (1.19, 1.35)
1.22 (1.16, 1.27)
1.20 (1.10, 1.30)
1.23 (1.20, 1.27)
0.95 (0.67, 1.37)
0.81 (0.70, 0.95)
0.74 (0.62, 0.90)
0.86 (0.74, 0.99)
0.80 (0.62, 1.04)
0.82 (0.75, 0.89)
1.07 (0.72, 1.59)
1.26 (1.10, 1.44)
1.27 (1.08, 1.49)
1.37 (1.22, 1.55)
1.61 (1.30, 1.99)
1.33 (1.24, 1.43)
Fig. 1.Hazard ratios, stratiﬁedby study and sex andadjusted for age and smoking, for coronaryheart disease associatedwith 1 standarddeviation increase of lipids among bodymass index
categories. BMI, body mass index; HDL cholesterol, high density lipoprotein cholesterol; HR, hazard ratio; CI, conﬁdence interval. Triglycerides were log-transformed. Bars show 95% CIs.
The diamonds show overall results across all BMI categories. The vertical diagonal of the diamond indicates the estimate and the horizontal diagonal indicates the 95% CIs.
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and TG (Supplementary Figure 5). There were no signiﬁcant differences
between subgroups (all p N 0.15 for interaction). Compared with indi-
viduals with a normal weight and TC b 4.4 mmol/l, the risk of CHD in-
creased independently with the elevation of BMI or TC levels, and was
3.2 times as high for obese individuals with TC ≥ 5.8mmol/l (HR adjust-
ed for age and smoking, 3.2; 95% CI, 2.5–4.0) (Supplementary Figure 6).
The effects of BMI on the association between high density lipoprotein cho-
lesterol and coronary heart disease
There were similar patterns of decreasing risk of CHD with increas-
ing HDLC across all BMI categories in the age- and smoking-adjusted
model, except for underweight individuals where there was no evi-
dence of association, although the number at risk was small (Supple-
mentary Figure 1). There was no evidence of difference in the effects
of HDLC across BMI categories (p = 0.95 for trend) (Fig. 1). The risk of
CHD decreased by 16% (95% CI, 11%–25%) for a 1 standard deviation in-
crease in HDLC. These associations were unchanged after left-censoring
by 2 years (Supplementary Figure 2), and after excluding participants
with non-fasting blood samples (Supplementary Figure 3) but were
slightly strengthened after additional adjustment for SBP and diabetes
(Supplementary Figure 4), and further attenuated after further adjust-
ment for other lipids (Supplementary Figure 5). There was no signiﬁ-
cant difference between subgroups (all p N 0.15 for interaction).
Compared with individuals of normal weight in the lowest quarter of
HDLC, the risk of CHD decreased as HDLC levels increased. These associ-
ations were less evident for underweight individuals with lower risk of
CHD, irrespective of HLDC levels (Supplementary Figure 6).
The effects of BMI on the association between triglycerides and coronary
heart disease
There were positive linear associations of TG with CHD, irrespective
of BMI category in the age and smoking-adjustedmodel (SupplementaryFigure 2). Comparing the effects of TG across all BMI categories, there
was a signiﬁcant trend of increasing effects of TG with increasing BMI
(p=0.01 for trend) (Fig. 1). Sensitivity analyses showed the consistency
of these associations after left-censoring by 2 years (Supplementary
Figure 2), after excluding participants with non-fasting blood samples
(Supplementary Figure 3) and after adjusting for age, smoking,
systolic blood pressure and diabetes (supplementary ﬁgure 4). When
further adjustment was made for TC and HDLC, these associations were
much attenuated, and not signiﬁcant (p = 0.07) (Supplementary
Figure 5). There were no signiﬁcant differences between subgroups (all
p N 0.20 for interaction). The risk of CHD for obese individuals with
TG ≥ 1.7 mmol/l was triple that of those of normal weight with
TG b 0.9 mmol/l (HR adjusted for age and smoking, 3.0; 95% CI,
2.0–4.5)) (Supplementary Figure 6).
Supplementary Figures 7–9 show sensitivity analyses wherein we:
combined the ﬁrst and last two BMI groups; classiﬁed BMI into its
equal ﬁfths and omitted the smallest and largest 0.1% of values of each
respective lipid—otherwise analysing as for Fig. 1. None of these chang-
es had any important effect on the results.
Discussion
This is the ﬁrst large-scale international study to investigate the ef-
fects of BMI on the association between lipid variables and the risk of
CHD. We found that the risk of CHD was positively associated with in-
creased TC and decreased HDLC, independently of BMI. On the other
hand, there was a signiﬁcant increase in the effects of TG on CHD with
increasing BMI, which was still evident after adjusting for HDLC and TC.
Whilst BMI and lipids are often considered as separate cardiovascu-
lar risk factors, for example in the Framingham Risk Equation, BMI acts
partially through lipids. Similarly, TC is partially determined by the diet,
but is also synthesised de novo, and excess adiposity is known to play a
role in this process. The underlying mechanism relating BMI, TG and
CHD is complex. The common form of high TG and low HDLC is charac-
teristic of themetabolic syndromewith abdominal obesity and diabetes
82 Y. Hirakawa et al. / Preventive Medicine Reports 3 (2016) 79–82and of background insulin resistance (Kannel and Vasan, 2009). TG and
HDLC have a close inverse relationship as cholesterol is transferred from
HDLC to TG-rich very low density lipoprotein (Feingold and Grunfeld,
2000). This proﬁle is amarker for the underlying presence of highly ath-
erogenic small dense low density lipoprotein cholesterol particles that
penetrate the intima (Rajman et al., 1999) and are subject to oxidation
(Tribble et al., 1992). In our analyses, the interaction of TG with BMI
was attenuated but still positive after adjusting for HDLC and TC, a ﬁnd-
ing reﬂecting the atherogenic effects of the mixed dyslipidemia in obe-
sity and the metabolic syndrome.
The presentﬁndings have public health implications in terms of spe-
ciﬁc education and health promotion measures to combat the obesity
epidemic as well as the associated lipid disorders. Traditionally, targets
for lipid lowering have ranged from TC/HDLC ratios (as in the Framing-
hamRisk Equation) to LDLC (inmultiple statin trials) to themore recent
guidelines (established clinical disease or high calculated risk scores).
Although severe hypertriglyceridemia should beneﬁt from drug inter-
vention (Berglund et al., 2012), lifestyle modiﬁcation is still important
for initial therapy and for patients with mild-to-moderate levels of TG.
A CHD risk equation incorporating BMI and TG and their interaction
would be useful to stratify individual risk and to determine a threshold
for therapy.
The strength of our study is the large sample size that allows us to
produce reliable estimates using several categories for lipid variables
and BMI. A limitation is the lack of standard methods of data collection
across the cohorts and a possible misclassiﬁcation of events that could
not always be veriﬁed using medical record or through autopsy data.
In addition, information on the use of lipid lowering medications was
not generally available. Our ﬁndings of statistical signiﬁcance should
be interpreted with the caveat that clinical and statistical signiﬁcance
are different issues.
To conclude, anthropometric and lipid variables are both strong pre-
dictors of CHD. BMI appears act independently of total and HDL choles-
terol, yet high BMI exacerbates the effects of TG on CHD. This association
was attenuated after adjusting for the other lipids but remained signif-
icant. Our study emphasizes the beneﬁts of bodyweight control togeth-
er with management of dyslipidemia to reduce the burden of CHD.Conﬂict of interest statement
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